Short answer
Protalix BioTherapeutics, Inc. (PLX) filed an 8-K current report with the SEC on March 18, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). FY 2025 financial results and business update announced via press release on March 18, 2026.
Protalix BioTherapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- FY 2025 financial results and business update announced via press release on March 18, 2026
- Financial details and clinical progress to be found in Exhibit 99.1 of this 8-K filing
- As per SEC rules, information not "filed" under Exchange Act Section 18, limiting legal liability for accuracy
- Results not automatically incorporated into future SEC filings unless explicitly referenced
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Protalix BioTherapeutics, Inc. 8-K filings
Get the next PLX 8-K as it lands
Follow PLX for push alerts, or ask the research agent what this filing means.